A case of advanced rectal cancer responding to l-Leucovorin (LV)/5-fluorouracil( 5-FU) therapy as neoadjuvant chemotherapy (Q46893154)

26 December 2017

title

A case of advanced rectal cancer responding to l-Leucovorin (LV)/5-fluorouracil( 5-FU) therapy as neoadjuvant chemotherapy (English)

1 reference

26 December 2017

1 reference

Yoshikazu Fukuda

1

1 reference

26 December 2017

Nagahisa Fujio

2

1 reference

26 December 2017

Toshio Ihara

3

1 reference

26 December 2017

Takashi Tsukazaki

4

1 reference

26 December 2017

Hiroshi Takatori

5

1 reference

26 December 2017

Ikuho Koyama

6

1 reference

26 December 2017

Yoshito Tsukazaki

7

1 reference

26 December 2017

Harushi Ohsugi

8

1 reference

26 December 2017

language of work or name

Japanese

0 references

publication date

1 January 2006

1 reference

26 December 2017

Japanese Journal of Cancer and Chemotherapy

published in

1 reference

26 December 2017

volume

33

1 reference

26 December 2017

page(s)

119-122

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

Hyperglycemia and cardiovascular disease

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Oxidative stress and diabetic vascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Insulin resistance and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Carvedilol: a nonselective beta blocking agent with antioxidant properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Carvedilol reduces mitochondrial damage induced by hypoxanthine/xanthine oxidase: relevance to hypoxia/reoxygenation injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Carvedilol, an Antihypertensive Drug with Antioxidant Properties, Protects against Glycerol-Induced Acute Renal Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Carvedilol and trimetazidine attenuates ferric nitrilotriacetate-induced oxidative renal injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Carvedilol decreases elevated oxidative stress in human failing myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

A review on the role of antioxidants in the management of diabetes and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic patients; a randomized, double-blind placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.3.1.119

21 January 2018

Identifiers

DOI

10.2217/14750708.3.1.119

1 reference

26 December 2017

PubMed ID

16410711

1 reference

26 December 2017